BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update
April 29 2020 - 06:00AM
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in
developing innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today, that the
Company will hold a conference call to update shareholders on
financial results for the first quarter ended March 31, 2020,
and provide a corporate update, at 8:30 a.m, Eastern Daylight Time,
on Thursday, May 7, 2020.
BrainStorm’s CEO, Chaim Lebovits, will
present a corporate update, after which, participant questions will
be answered. Joining Mr. Lebovits to answer investment community
questions will be Ralph Kern, MD, MHSc, President and Chief
Medical Officer, David Setboun, PhD, MBA, Executive Vice President
and Chief Operating Officer and Preetam Shah, PhD, MBA,
Executive Vice President and Chief Financial Officer.
Participants are encouraged to submit their
questions prior to the call by sending them
to: q@brainstorm-cell.com. Questions should be submitted
by 5:00 p.m. EDT, Tuesday, May 5, 2020.
Teleconference Details – BRAINSTORM CELL
THERAPEUTICS 1Q 2020
The investment community may participate in the
conference call by dialing the following numbers:
Participant Numbers: |
Toll
Free: 877-407-9205 International: 201-689-8054 |
Those interested in listening to the conference
call live via the internet may do so by visiting the "Investors
& Media" page of BrainStorm's website at
www.ir.brainstorm-cell.com and clicking on the conference call
link.
Event Link: |
Webcast URL:
https://www.webcaster4.com/Webcast/Page/2354/34588 |
Webcast Replay
Expiration: |
Friday, August 07, 2020 |
Those that wish to listen to the replay of the
conference call can do so by dialing the numbers below. The replay
will be available for 14 days.
Replay Number: |
Toll
Free: 877-481-4010 International: 919-882-2331 Replay Passcode:
34588 |
Teleconference Replay
Expiration: |
Thursday, May 21, 2020 |
ABOUT NUROWN®NurOwn (autologous MSC-NTF cells)
represent a promising investigational approach to targeting disease
pathways important in neurodegenerative disorders. MSC-NTF cells
are produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. NurOwn® is
currently being evaluated in a Phase 3 ALS randomized
placebo-controlled trial and in a Phase 2 open-label multicenter
trial in Progressive MS.
ABOUT BRAINSTORM CELL THERAPEUTICS
INC.:BrainStorm Cell Therapeutics Inc. is a leading developer
of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the
NurOwn® Cellular Therapeutic Technology Platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement as well as through its own patents, patent
applications and proprietary know-how. Autologous MSC-NTF cells
have received Orphan Drug status designation from the U.S.
Food and Drug Administration (U.S. FDA) and
the European Medicines Agency (EMA) in ALS. BrainStorm
has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056),
investigating repeat-administration of autologous MSC-NTF cells at
six sites in the U.S., supported by a grant from
the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a BLA filing
for U.S. FDA approval of autologous MSC-NTF cells in ALS.
BrainStorm received U.S. FDA clearance to initiate a
Phase 2 open-label multi-center trial of repeat intrathecal dosing
of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718)
in December 2018 and has been enrolling clinical trial
participants since March 2019. For more information, visit the
company's website.
SAFE HARBOR
STATEMENT:Statements in this announcement other than
historical data and information, including statements regarding
future clinical trial enrollment and data, constitute
"forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics
Inc.'s actual results to differ materially from those stated
or implied by such forward-looking statements. Terms and phrases
such as "may", "should", "would", "could", "will", "expect",
"likely", "believe", "plan", "estimate", "predict", "potential",
and similar terms and phrases are intended to identify these
forward-looking statements. The potential risks and uncertainties
include, without limitation, BrainStorm’s need to raise additional
capital, BrainStorm’s ability to continue as a going concern,
regulatory approval of BrainStorm’s NurOwn® treatment candidate,
the success of BrainStorm’s product development programs and
research, regulatory and personnel issues, development of a global
market for our services, the ability to secure and maintain
research institutions to conduct our clinical trials, the ability
to generate significant revenue, the ability of BrainStorm’s
NurOwn® treatment candidate to achieve broad acceptance as a
treatment option for ALS or other neurodegenerative diseases,
BrainStorm’s ability to manufacture and commercialize the NurOwn®
treatment candidate, obtaining patents that provide meaningful
protection, competition and market developments, BrainStorm’s
ability to protect our intellectual property from infringement by
third parties, heath reform legislation, demand for our services,
currency exchange rates and product liability claims and
litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTS Investor
Relations: Preetam Shah, MBA, PhD Chief Financial Officer
BrainStorm Cell Therapeutics Inc. Phone: + 1.862.397.1860
pshah@brainstorm-cell.com Media: Sean Leous
Westwicke/ICR PR Phone: +1.646.677.1839 sean.leous@icrinc.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2023 to Mar 2024